{
    "abstract": "Dealing with life-threatening viral acute respiratory distress syndrome (ARDS) has always been challenging and with the recent COVID pandemic experience, there is still the need of newer therapies to alleviate mortality. Aviptadil, has shown significant beneficial results in covid. We share our experience with this molecule by doing a retrospective study to evaluate the effect of this drug on clinical outcomes in viral-related Ards patients.\nIn this study, all patients with severe viral-related Ards received Aviptadil along with the conventional treatment. The oxygen saturation, SpO\nA total of 68 patients with viral pneumonias were admitted to intensive care unit (Icu) and only 6 patients had severe Ards, who received Aviptadil. The mean oxygen saturation significantly improved from 87.86% before the first Aviptadil dose to 93.43% post 3 days of infusion. Similarly, improvement was seen in PaO\nAviptadil has shown to improve the clinical outcomes in patients with severe viral-related ards without any adverse effects.\nSampley S, Bhasin D, Sekhri K, Singh H, Gupta O. Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS: A Retrospective Observational Study. Indian J Crit Care Med 2024;28(1):70-74.",
    "authors": [
        {
            "affiliation": "Medical Intensive Care Unit, Max Super Speciality Hospital, Mohali, Punjab, India.",
            "firstname": "Supriya",
            "initials": "S",
            "lastname": "Sampley"
        },
        {
            "affiliation": "Department of Pulmonology and Critical Care, Max Super Speciality Hospital, Mohali, Punjab, India.",
            "firstname": "Deepak",
            "initials": "D",
            "lastname": "Bhasin"
        },
        {
            "affiliation": "Department of Pharmacology, Dr. Harvansh Singh Judge Institute of Dental Sciences and Hospital, Punjab University, Chandigarh, India.",
            "firstname": "Kavita",
            "initials": "K",
            "lastname": "Sekhri"
        },
        {
            "affiliation": "Department of Pulmonology and Critical Care, Max Super Speciality Hospital, Mohali, Punjab, India.",
            "firstname": "Harpal",
            "initials": "H",
            "lastname": "Singh"
        },
        {
            "affiliation": "Department of Pulmonology and Critical Care, Max Super Speciality Hospital, Mohali, Punjab, India.",
            "firstname": "Onkar",
            "initials": "O",
            "lastname": "Gupta"
        }
    ],
    "conclusions": "Aviptadil has shown to improve the clinical outcomes in patients with severe viral-related ards without any adverse effects.",
    "copyrights": "Copyright \u00a9 2024; The Author(s).",
    "doi": "10.5005/jp-journals-10071-24594\n10.1007/s00134-003-2022-6\n10.1056/NEJMoa050333\n10.1111/nyas.12462\n10.3390/pathogens5040066\n10.1164/rccm.201212-2341OC\n10.3389/fimmu.2018.00320\n10.1016/j.cell.2011.08.015\n10.1016/j.cell.2020.03.045.e9\n10.1016/j.fct.2020.111769\n10.1038/225863a0\n10.4049/jimmunol.170.1.308\n10.1016/j.molmed.2007.04.003\n10.1152/ajplung.1990.259.2.L151\n10.4049/jimmunol.176.1.97\n10.1097/CCE.0000000000000607\n10.2139/ssrn.3679909\n10.1097/CCM.0000000000005660\n10.1016/S2213-2600(23)00147-9",
    "journal": "Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine",
    "keywords": [
        "Aviptadil",
        "Viral acute respiratory distress syndrome",
        "Viral pneumonia"
    ],
    "methods": null,
    "publication_date": "2024-03-21",
    "pubmed_id": "38510776\n14569423\n16236739\n24891213\n27929449\n23855650\n29556226\n21925319\n32275855\n32979398\n5415118\n12496414\n17467339\n2382732\n16365400\n35018346\n36044317\n37348524",
    "results": "A total of 68 patients with viral pneumonias were admitted to intensive care unit (Icu) and only 6 patients had severe Ards, who received Aviptadil. The mean oxygen saturation significantly improved from 87.86% before the first Aviptadil dose to 93.43% post 3 days of infusion. Similarly, improvement was seen in PaO",
    "title": "Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS: A Retrospective Observational Study.",
    "xml": "<Element 'PubmedArticle' at 0x788504581df0>"
}